Department of Breast Medical Oncology, University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030-1439, USA.
Expert Opin Drug Saf. 2010 Nov;9(6):995-1003. doi: 10.1517/14740338.2010.515977.
Anastrozole is a third-generation aromatase inhibitor used in the adjuvant setting for the treatment of hormone receptor-positive breast cancer. Several adjuvant randomized trials have reported greater efficacy for anastrozole when compared to tamoxifen.
This review discusses the mechanism of action of anastrozole; pharmacokinetic and pharmacodynamic characteristics; results of randomized controlled trials of anastrozole compared to tamoxifen in the adjuvant treatment of postmenopausal women with hormone receptor-positive breast cancer and the safety profile of anastrozole compared to tamoxifen.
The reader will gain an understanding of the basic pharmacology of anastrozole, efficacy data from clinical trials comparing anastrozole to tamoxifen, safety profile of anastrozole and ongoing areas of research.
The adverse effects of anastrozole.
重要性领域：阿那曲唑是第三代芳香化酶抑制剂，用于激素受体阳性乳腺癌的辅助治疗。与他莫昔芬相比，几项辅助随机试验报告了阿那曲唑更大的疗效。
涵盖范围：本综述讨论了阿那曲唑的作用机制；药代动力学和药效学特征；与他莫昔芬相比，阿那曲唑在激素受体阳性绝经后妇女辅助治疗中的随机对照试验结果，以及与他莫昔芬相比，阿那曲唑的安全性概况。
读者将获得：读者将了解阿那曲唑的基本药理学、比较阿那曲唑和他莫昔芬的临床试验疗效数据、阿那曲唑的安全性概况以及正在进行的研究领域。
结论：阿那曲唑的不良反应。
